Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131802 | 0.88 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4141300 | 0.88 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4138246 | 0.85 | PIK3CA (0.67) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4133829 | 0.84 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4143852 | 0.84 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4138240 | 0.80 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4140294 | 0.80 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CGPIK3CDMAPT | |
| SCHEMBL4128479 | 0.80 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4138231 | 0.79 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4147474 | 0.79 | ABCG2 (0.60) | PIK3CAPIK3CBPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | claimed |
| EP-1945627-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2008-07-23 | — | — | EP | claimed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | claimed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1945627-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PIK3CA 137/4885PIK3CB 377/4885PIK3CG 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.